secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017852
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q1 revenue $100.5M (+26% YoY); net loss $164M; reaffirms FY 2023 guidance
--------------------------------------------------------------------------------

- Crysvita revenue $76M (+28% YoY), Dojolvi $14.3M (+15%), Mepsevii $8.5M.
- Net loss per share $2.33 vs $2.19 in Q1 2022; op ex $254.6M incl $31.9M stock comp.
- Cash & equivalents $714.6M; reaffirms FY 2023 total revenue $425-450M, net cash used <$400M.
- UX143 OI Phase 2 complete, data & Phase 3 initiation expected mid-2023.
- GTX-102 expansion cohorts dosing; next data update in 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023017852/0000950170-23-017852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023017852/rare-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer